Exploratory Study on the Potential Cross-System Effects of BCI-FES Hand Therapy on Dysphagia and Aphasia in Chronic Stroke Patients

Inclusion Criteria: * Age: Participants must be aged 18 years or older. * Post-Stroke Phase: Participants must be within the chronic post-stroke phase (time since ischemic or haemorrhagic stroke greater than 3 months). * Motor Impairment: Participants must exhibit disabling left or right residual arm paresis ("left/right arm motor drift" part of the NIHSS score ≥1). * Speech/Swallowing Impairment: Participants must have: * Aphasia (AAT-Skala zum Kommunikationsverhalten score ≤3), and/or * Dysphagia (MUCCS-N score ≥2). * Stable Neurological Status: No relevant changes in neurological status in the past 4 weeks (self-reported). * Motor Function: Participants must be able to raise at least 1 block similar to the ones in Box-and-Block-Test. * Cognitive Understanding: Participants must be able to understand basic spoken instructions. * Sitting Tolerance: Participants must be able to maintain a sitting position for at least 60 minutes. * Willingness to Participate: Participants must be willing to participate in the study and able to understand and sign the informed consent. Exclusion Criteria: * Cognitive Impairments: Cognitive impairments that, in the investigator's judgment, could limit understanding of task instructions. * Stroke Location: Participants with a brainstem and/or cerebellar stroke. * Previous Stroke: Participants with a previous disabling stroke. * Hemi-Neglect: Pronounced hemi-neglect at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment). * Anosognosia: Pronounced anosognosia at the last documented therapy visit that limits compliance with treatment intervention (investigator's judgment). * Spasticity: Severe spasticity in the affected limb, resulting in complete rigidity in flexion or extension. * Seizure Disorders: Participants with uncontrolled epilepsy (investigator's judgement) or epileptic seizure within the last month. * Intracranial Pressure: Known ongoing elevated intracranial pressure. * Implanted Medical Devices: Participants with implanted medical devices with contraindication for FES such as pacemakers. * Metallic Fragments: Participants with implanted metallic fragments in the extremity planned for FES that would limit the use of functional electrical stimulation (FES). * Unhealed Injuries: Unrecovered fractures or skin/tissue lesions in the FES stimulated extremity. * Joint Issues: Ossification, contraction, or stiffness of the wrist joint in the FES stimulated extremity that would limit treatment. * Botulinum Toxin: Participants who received botulinum-toxin treatment within 6 weeks prior to study inclusion and/or for whom botulinum-toxin treatment is planned during the study duration. * Co-morbidities: The following conditions will exclude participation: * Chronic Obstructive Pulmonary Disease (Stage IV). * Cardiac insufficiency (NYHA Stage IV). * Severe acute infections. * Significant circulatory disturbances in the stimulated extremity. * Sensory disorders that significantly impair the patient's ability to feel pain or react to unsuitable proprioceptive stimuli. * Any other general medical conditions that, in the investigator's judgment, limit the safety or performance of study procedures (investigator's judgement). * Electrical Stimulation Intolerance: Known inability to tolerate cutaneous electrical stimulation.